The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Open accessAbstract
flammatory milieu, which likely contributes to both of these disease states.The hyperglycemic, hyperinsulinemic, insulin-resistant state is proinflammatory and is very different than the euglycemic, hyperinsulinemic state achieved with intensive insulin therapy.Insulin itself possesses anti-inflammatory properties (2).Intranuclear levels of nuclear factor , important in cancer progression, as well as plasma levels of several inflammatory cytokines (including vascular endothelial cell growth factor, i.e., vascular endothelial growth factor) are reduced through intravenous insulin infusion in obese nondiabetic subjects (3,4).Reduction in plasma vascular endothelial growth factor levels has also been shown during insulinization of poorly controlled or newly diagnosed diabetic adults and children (5,6).These data suggest that insulin possesses antiangiogenic as well as antiinflammatory properties, which could benefit oncologic patients.As the authors point out, establishing a cause-and-effect relationship by a retrospective study in such a complex population is not possible.The positive or negative effects of aggressive insulinization in cancer patients remains an opened question that urgently requires randomized controlled clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Self-citation
Cited by
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
“Clinically, this concept is supported by retrospective record-linkage casecontrol studies demonstrating that metformin treatment of diabetic patients reduced the risk of certain cancers (Bowker et al., 2006; Libby et al., 2009), whereas insulin mimetics could increase such risks.”
ResultAlimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
State of the art paper Sulfonylureas and their use in clinical practice
Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.53304 · Cited by 514
Phan, L. M., Yeung, S. J., & Lee, M. H. (2014) · PubMed · doi:10.7497/j.issn.2095-3941.2014.01.001 · Cited by 490
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
AMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth
Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383
The fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
RIEGER, J., BÄHR, O., MAURER, G. D., HATTINGEN, E., FRANZ, K., BRUCKER, D., WALENTA, S., KÄMMERER, U., COY, J. F., WELLER, M., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2382 · Cited by 287
Storozhuk, Y., Hopmans, S. N., Sanli, T., Barron, C., Tsiani, E., Cutz, J.-C., Pond, G., Wright, J., Singh, G., & Tsakiridis, T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.187 · Cited by 273
Risk of cancer in a large cohort of U.S. veterans with diabetes
Atchison, E. A., Gridley, G., Carreon, J. D., Leitzmann, M. F., & McGlynn, K. A. (2011) · International Journal of Cancer · doi:10.1002/ijc.25362 · Cited by 257
Vazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250
“15-25 Interestingly, the ability of metformin to drastically downregulate HER2 oncoprotein expression appears to work independently of AMPK when considering the following findings: (1) Compound C, an inhibitor of AMPK, does not entirely prevent the downregulation of HER2 occurring upon metformin treatment; (2) the AMP…”
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176
Glucose Promotes Breast Cancer Aggression and Reduces Metformin Efficacy
Wahdan-Alaswad, R., Fan, Z., Edgerton, S. M., Liu, B., Deng, X.-S., Arnadottir, S. S., Richer, J. K., Anderson, S. M., & Thor, A. D. (2013) · Cell Cycle · doi:10.4161/cc.26641 · Cited by 125
Liu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16359 · Cited by 120
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Management of pancreatogenic diabetes: challenges and solutions
Makuc, J. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s99701 · Cited by 84
Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor Behind the Scene
Anwar, M. A., Kheir, W. A., Eid, S., Fares, J., Liu, X., Eid, A. H., & Eid, A. A. (2014) · Journal of Cancer · doi:10.7150/jca.9726 · Cited by 35
Xin, W.-X., Fang, L., Fang, Q.-L., Zheng, X.-W., Ding, H.-Y., & Huang, P. (2018) · Medicine · doi:10.1097/md.0000000000010035 · Cited by 18
Metadata
- Authors
- Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-08-01
- Volume
- 29
- Issue
- 8
- Pages
- 1990-1991
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1980359753
- Cited by
- 175
- References
- 1
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.